Myelodysplastic Syndromes (MDS IWG, IPSSM, NEJM Evidence 2022)

Summary

Myelodysplastic Syndromes (MDS IWG, IPSSM, NEJM Evidence 2022) is a study catalogued by cBioPortal DataHub under the cancer-type code mds. EvidenceHelix groups it with blood, lymph and bone marrow studies.

Study description

International Working Group for the prognosis of Myelodysplastic Syndromes. Derivation of the Molecular International Prognosis Scoring System for MDS. Comprehensive profiling of 3,323 treatment-naive MDS samples. Data generated by the Papaemmanuil Lab 2022.

Text as published in the source's study metadata.

Citation & PubMed

Bernard et al. NEJM Evidence 2022

Source & licence

Metadata from cBioPortal DataHub at e1b75cd25b, available under the ODC Open Database License (ODbL) 1.0. See the Source metadata tab for every field.

Source metadata

Study identifier

mds_iwg_2022

Short name

not given

Source cancer-type code

mds

Reference genome

hg19

Source access groups

PUBLIC

Original study

View on cBioPortal

Metadata file

meta_study.txt at e1b75cd25b

Database licence

ODC Open Database License (ODbL) 1.0

Study-level metadata only (title, description, cancer-type code, citation, PubMed ids). No patient, sample, mutation or clinical data, and no publication full text, is included. Individual studies may carry their own terms; follow each study's source links before reusing its data.

Citations

Bernard et al. NEJM Evidence 2022

Citation counts are not part of the source metadata and are not shown.

Related studies

• Acute Lymphoblastic Leukemia (St Jude, Nat Genet 2015)

  Comprehensive profiling of infant MLL-rearranged acute lymphoblastic leukemia (MLL-R ALL)

  Blood, lymph and bone marrowOther published and consortium studiesSource code bllPubMed 1

• Acute Lymphoblastic Leukemia (St Jude, Nat Genet 2016)

  Whole-genome and/or whole-exome sequencing of ERG-altered B-ALL tumor/normal pairs.

  Blood, lymph and bone marrowOther published and consortium studiesSource code bllPubMed 1

• Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)

  Whole-exome and transcriptomic sequencing of 942 acute myeloid leukemia samples (with 500 matched normals) from the Beat AML program.

  Blood, lymph and bone marrowOther published and consortium studiesSource code amlPubMed 1

• Acute Myeloid Leukemia (OHSU, Nature 2018)

  Whole-exome sequencing of 672 acute myeloid leukemia samples (with 454 matched normals) from the Beat AML program.

  Blood, lymph and bone marrowOther published and consortium studiesSource code amlPubMed 1

• Acute myeloid leukemia or myelodysplastic syndromes (WashU, 2016)

  Enhanced exome or targeted sequencing of 116 acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) patients' tumor/normal pairs .

  Blood, lymph and bone marrowOther published and consortium studiesSource code mnmPubMed 1

• Chronic Lymphocytic Leukemia (Broad, Cell 2013)

  Whole-exome sequencing of 160 CLL tumor/normal pairs.

  Blood, lymph and bone marrowOther published and consortium studiesSource code cllsllPubMed 1

• Chronic Lymphocytic Leukemia (Broad, Nature 2015)

  Whole exome sequencing of 537 chronic lymphocytic leukemia tumor/normal pairs.

  Blood, lymph and bone marrowOther published and consortium studiesSource code cllsllPubMed 1

• Chronic Lymphocytic Leukemia (Broad, Nature Genetics 2022)

  Whole genome and whole exome sequencing of 1,154 samples from 1,148 patients with Chronic Lymphocytic Leukemia and monoclonal B cell lymphocytosis and their matched normals.

  Blood, lymph and bone marrowOther published and consortium studiesSource code cllsllPubMed 1

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.